SENSEX    74339.44       486.50    |    NIFTY    22570.35       167.95 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Stock Alert
Overall view of all the recent market developments which will help in your investment decisions
Lupin in focus as EU Court upholds fine in Perindopril litigation
13-Dec-18   08:37 Hrs IST

Lupin announced that the General Court of the European Union has delivered its judgment concerning Lupin's and other companies appeal against the European Commission's (EC) 2014 decision in the Perindopril litigation. The General Court upheld the EC's decision holding Lupin liable to pay a fine of EUR 40 million. Lupin will study the General Court's judgment and evaluate further course of action. The announcement was made after market hours yesterday, 12 December 2018.

DLF said that the company's board of directors has considered and approved offering upto 17.30 crore equity shares in one or more tranches by way of private placement, including Qualified Institutions Placement (QIP). The announcement was made after market hours yesterday, 12 December 2018.

Indian Oil Corporation's board meets today to consider and approve buyback of equity shares and interim dividend.

Strides Pharma Science (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug Administration (US FDA). Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP. The announcement was made after market hours yesterday, 12 December 2018.

Infibeam Incorporation said that the meeting of the board of directors of the company is scheduled on 17 December 2018 to consider and approve examine and evaluate the feasibility of and options for strategic growth opportunities of the business verticals and subsidiaries of the company. The announcement was made after market hours yesterday, 12 December 2018.

Powered by Capital Market - Live News

MARKETS
TODAY'S MARKET SECTOR
BSE NSE
Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.86 88.96 1.07
United Kingdom (GBP) 1.16 1.00 103.28 1.24
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.94 0.81 83.31 1.00
Market News << ALL News
  25-Apr-2024, (05:52 )  IndusInd Bank Q4 PAT..
  25-Apr-2024, (04:53 )  Tech Mahindra Q4 PAT..
  25-Apr-2024, (04:33 )  Laurus Labs slides a..
  25-Apr-2024, (04:32 )  ACC records four-fol..
 Commodities << ALL Commodities
   Attention Investor: Prevent unauthorized transactions in your trading / Demat account : Update your mobile number / e mail ids with your stock broker / deposit." | "No need to issue cheques by investors while subscribing to IPO.Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account." | "KYC is one time exercise while dealing in securities markets- once KYC is done through a SEBI registered intermediary(broker, DP, Mutual Fund etc.) you need not undergo the same process again when you approach another intermediary."
   Disclaimer   |   BSE Disclosure  |  Privacy Policy   |   Investor Protection   |    Inactive Account   |  Vernacular Language: NSE | BSE   |   Feedback   |    PMLA Policy   |   Risk Management Policy   |   Insider Trading   |   Investor Grivenances   |   Investor Complaints   |   Investor Charter   |   Rules And Regulations   |   Broker Norms   |   Terms of Use    Policies & Procedures   |   Risk Disclosure   |   Do & Don’ts   |   Rights & Obligations
  
SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)